148 related articles for article (PubMed ID: 37516313)
1. Repetitive ambulatory levosimendan as a bridge to heart transplantation.
de Juan Bagudá J; de Frutos F; López-Vilella R; Couto Mallón D; Guzman-Bofarull J; Blazquez-Bermejo Z; Cobo-Belaustegui M; Mitroi C; Pastor-Pérez FJ; Moliner-Abós C; Rangel-Sousa D; Díaz-Molina B; Tobar-Ruiz J; Salterain Gonzalez N; García-Pinilla JM; García-Cosío Carmena MD; Crespo-Leiro MG; Dobarro D; Almenar L; Delgado-Jiménez JF; Paredes-Galán E; González-Vílchez F; González-Costello J
Rev Esp Cardiol (Engl Ed); 2024 Apr; 77(4):290-301. PubMed ID: 37516313
[TBL] [Abstract][Full Text] [Related]
2. Economic analysis of intermittent intravenous outpatient treatment with levosimendan in advanced heart failure in Spain.
Manito Lorite N; Rubio-Rodríguez D; González Costello J; Díez López C; Enjuanes Grau C; Segovia-Cubero J; Delgado Jimenez JF; Campo Sien C; Rubio-Terrés C; Comín-Colet J; ;
Rev Esp Cardiol (Engl Ed); 2020 May; 73(5):361-367. PubMed ID: 31899185
[TBL] [Abstract][Full Text] [Related]
3. Levosimendan in outpatients with advanced heart failure: Single-center experience of 200 intermittent perfusions.
Ferreira Reis J; Valentim Gonçalves A; Ilhão Moreira R; Pereira da Silva T; Timóteo AT; Pombo D; Carvalho T; Correia C; Santos C; Cruz Ferreira R
Rev Port Cardiol; 2023 Apr; 42(4):335-343. PubMed ID: 36634758
[TBL] [Abstract][Full Text] [Related]
4. Levosimendan as a bridge to heart transplant: a real alternative.
Goirigolzarri-Artaza J; Restrepo-Córdoba MA
Rev Esp Cardiol (Engl Ed); 2024 Apr; 77(4):302-303. PubMed ID: 38104926
[No Abstract] [Full Text] [Related]
5. Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry.
Dobarro D; Donoso-Trenado V; Solé-González E; Moliner-Abós C; Garcia-Pinilla JM; Lopez-Fernandez S; Ruiz-Bustillo S; Diez-Lopez C; Castrodeza J; Méndez-Fernández AB; Vaqueriza-Cubillo D; Cobo-Marcos M; Tobar J; Sagasti-Aboitiz I; Rodriguez M; Escolar V; Abecia A; Codina P; Gómez-Otero I; Pastor F; Marzoa-Rivas R; González-Babarro E; de Juan-Baguda J; Melendo-Viu M; de Frutos F; Gonzalez-Costello J
ESC Heart Fail; 2023 Apr; 10(2):1193-1204. PubMed ID: 36655614
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).
Moiseyev VS; Põder P; Andrejevs N; Ruda MY; Golikov AP; Lazebnik LB; Kobalava ZD; Lehtonen LA; Laine T; Nieminen MS; Lie KI;
Eur Heart J; 2002 Sep; 23(18):1422-32. PubMed ID: 12208222
[TBL] [Abstract][Full Text] [Related]
7. Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials.
Huang X; Lei S; Zhu MF; Jiang RL; Huang LQ; Xia GL; Zhi YH
J Zhejiang Univ Sci B; 2013 May; 14(5):400-15. PubMed ID: 23645177
[TBL] [Abstract][Full Text] [Related]
8. Single-centred experience with levosimendan in paediatric decompensated dilated cardiomyopathy.
Séguéla PE; Mauriat P; Mouton JB; Tafer N; Assy J; Poncelet G; Nubret K; Iriart X; Thambo JB
Arch Cardiovasc Dis; 2015; 108(6-7):347-55. PubMed ID: 25863426
[TBL] [Abstract][Full Text] [Related]
9. Repetitive use of LEvosimendan in Ambulatory Heart Failure patients (LEIA-HF) - The rationale and study design.
Tycińska A; Gierlotka M; Bartuś S; Gąsior M; Główczyńska R; Grześk G; Jaguszewski M; Kasprzak JD; Kubica J; Legutko J; Leszek P; Nessler J; Pacileo G; Ponikowski P; Sobkowicz B; Stępińska J; Straburzyńska-Migaj E; Wojakowski W; Zawiślak B; Zymliński R;
Adv Med Sci; 2022 Mar; 67(1):18-22. PubMed ID: 34656873
[TBL] [Abstract][Full Text] [Related]
10. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.
Cavusoglu Y
Expert Opin Pharmacother; 2007 Apr; 8(5):665-77. PubMed ID: 17376021
[TBL] [Abstract][Full Text] [Related]
11. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.
Cleland JG; Takala A; Apajasalo M; Zethraeus N; Kobelt G
Eur J Heart Fail; 2003 Jan; 5(1):101-8. PubMed ID: 12559222
[TBL] [Abstract][Full Text] [Related]
12. [Levosimendan treatment of severe acute congestive heart failure refractory to dobutamine/milrinone in children].
Prijić S; Rakić S; Nikolić L; Jovicić B; Stajević M; Vukomanović V; Kosutić J
Vojnosanit Pregl; 2011 Nov; 68(11):979-84. PubMed ID: 22191317
[TBL] [Abstract][Full Text] [Related]
13. Repeated Levosimendan Infusions in the Management of Advanced Heart Failure: Review of the Evidence and Meta-analysis of the Effect on Mortality.
Silvetti S; Pollesello P; Belletti A
J Cardiovasc Pharmacol; 2024 Feb; 83(2):144-157. PubMed ID: 37991393
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study.
García-González MJ; Aldea Perona A; Lara Padron A; Morales Rull JL; Martínez-Sellés M; de Mora Martin M; López Díaz J; López Fernandez S; Ortiz Oficialdegui P; Jiménez Sosa A
ESC Heart Fail; 2021 Dec; 8(6):4820-4831. PubMed ID: 34716753
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients undergoing surgery for congenital heart disease.
Hummel J; Rücker G; Stiller B
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD011312. PubMed ID: 28770972
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients undergoing surgery for congenital heart disease.
Hummel J; Rücker G; Stiller B
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011312. PubMed ID: 28262914
[TBL] [Abstract][Full Text] [Related]
17. Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery.
Mehta RH; Leimberger JD; van Diepen S; Meza J; Wang A; Jankowich R; Harrison RW; Hay D; Fremes S; Duncan A; Soltesz EG; Luber J; Park S; Argenziano M; Murphy E; Marcel R; Kalavrouziotis D; Nagpal D; Bozinovski J; Toller W; Heringlake M; Goodman SG; Levy JH; Harrington RA; Anstrom KJ; Alexander JH;
N Engl J Med; 2017 May; 376(21):2032-2042. PubMed ID: 28316276
[TBL] [Abstract][Full Text] [Related]
18. Short-term effect of levosimendan on free light chain kappa and lambda levels in patients with decompensated chronic heart failure.
Kurt IH; Yavuzer K; Batur MK
Heart Vessels; 2010 Sep; 25(5):392-9. PubMed ID: 20676961
[TBL] [Abstract][Full Text] [Related]
19. Levosimendan in patients with decompensated heart failure.
Rosa EM; Osório AP; Scopel L
Arq Bras Cardiol; 2008 Aug; 91(2):119. PubMed ID: 18709265
[No Abstract] [Full Text] [Related]
20. Intermittent inotropic therapy with levosimendan vs. milrinone in advanced heart failure patients.
Milwidsky A; Frydman S; Laufer-Perl M; Sadeh B; Sapir O; Granot Y; Hochstadt A; Korotetski L; Ketchker L; Topilsky Y; Banai S; Havakuk O
ESC Heart Fail; 2022 Apr; 9(2):1487-1491. PubMed ID: 35083882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
